Briacell Therapeutics Corp is facing a significant setback, with shares down 3.61% in the latest trading session.
Briacell Therapeutics Corp (BCT.TO) saw its stock price drop to CA$5.07 after a 3.61% decline. This downturn comes despite recent advancements in their clinical trials, raising questions about investor confidence in the company's future.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$45.76M
52W high
$20.40
52W low
$3.68
1W change
-4.50%
Beta
1.54
Analyst Price Targets
Based on analyst covering BCT
Wall Street analysts forecast BCT stock price to rise 292.9% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+292.9% Upside
Current Price
C$5.09
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
60.0%
Annualized
90-Day Vol
87.6%
Annualized
Trend (90d)
-0.8%
Annualized drift
90d Mean
C$5.08
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.09 | C$4.13 โ C$6.25 |
| 60 trading days | C$5.08 | C$3.79 โ C$6.81 |
| 90 trading days | C$5.08 | C$3.55 โ C$7.26 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should consider the implications of Briacell's recent stock performance and weigh the potential risks against the company's ongoing clinical developments.
Briacell's Market Cap Dips Below CA$46 Million
With a market cap of CA$45,760,880, Briacell's financial stability is under scrutiny as it navigates the challenges of clinical trials and investor expectations.
Bull case
Briacell's partnership with Sunnybrook's Odette Cancer Centre for its pivotal Phase 3 trial could boost its credibility and attract more investors if the results are positive.
Bear case
The recent stock decline may reflect broader market skepticism about the effectiveness of its therapies, especially considering the high stakes involved in clinical trial outcomes.
Recent Developments at Briacell
Briacell recently opened its first Canadian site at Sunnybrook for a pivotal Phase 3 trial in metastatic breast cancer, marking a significant milestone that could improve patient access to their innovative therapies. However, the stock's decline suggests that investors are cautious about the trial outcomes.
Market Reaction and Future Outlook
The market's response to Briacell's recent news has been lukewarm, as shown by the 3.61% drop in stock price. Investors may be worried about the company's ability to meet expectations amid the uncertainties surrounding clinical trial results. Given the volatility often seen in the biotechnology sector, it's important to keep an eye on Briacell's developments.
Advertisement
